Leerink Swann restated their market perform rating on shares of OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) in a research report report published on Friday.

Other equities analysts have also issued reports about the stock. Jefferies Group raised their price target on shares of OncoMed Pharmaceuticals from $15.00 to $16.00 and gave the stock a buy rating in a research report on Wednesday, August 10th. Cantor Fitzgerald reaffirmed a buy rating and set a $16.00 price target on shares of OncoMed Pharmaceuticals in a research report on Thursday, July 14th. HC Wainwright started coverage on shares of OncoMed Pharmaceuticals in a research report on Thursday, September 22nd. They set a buy rating and a $20.00 price target on the stock. Finally, Zacks Investment Research lowered shares of OncoMed Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. OncoMed Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $19.25.

OncoMed Pharmaceuticals (NASDAQ:OMED) opened at 9.74 on Friday. The firm’s market capitalization is $361.28 million. OncoMed Pharmaceuticals has a 12 month low of $8.07 and a 12 month high of $23.98. The stock’s 50 day moving average is $10.17 and its 200-day moving average is $11.51.

OncoMed Pharmaceuticals (NASDAQ:OMED) last released its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported ($0.77) EPS for the quarter, hitting analysts’ consensus estimates of ($0.77). OncoMed Pharmaceuticals had a negative net margin of 409.54% and a negative return on equity of 1,307.23%. The business had revenue of $5.92 million for the quarter, compared to analyst estimates of $9.48 million. During the same period last year, the firm earned ($0.81) earnings per share. OncoMed Pharmaceuticals’s revenue for the quarter was up 26.3% compared to the same quarter last year. Equities analysts anticipate that OncoMed Pharmaceuticals will post ($3.23) earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of the company. Alps Advisors Inc. increased its stake in OncoMed Pharmaceuticals by 25.7% in the second quarter. Alps Advisors Inc. now owns 42,562 shares of the biopharmaceutical company’s stock valued at $524,000 after buying an additional 8,701 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in OncoMed Pharmaceuticals by 1.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,821 shares of the biopharmaceutical company’s stock valued at $528,000 after buying an additional 588 shares in the last quarter. Candriam Luxembourg S.C.A. increased its stake in OncoMed Pharmaceuticals by 59.0% in the second quarter. Candriam Luxembourg S.C.A. now owns 167,000 shares of the biopharmaceutical company’s stock valued at $2,056,000 after buying an additional 62,000 shares in the last quarter. BVF Inc. IL increased its stake in OncoMed Pharmaceuticals by 35.1% in the first quarter. BVF Inc. IL now owns 1,339,336 shares of the biopharmaceutical company’s stock valued at $13,541,000 after buying an additional 347,903 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new stake in OncoMed Pharmaceuticals during the first quarter valued at approximately $832,000. Institutional investors and hedge funds own 31.94% of the company’s stock.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc.

5 Day Chart for NASDAQ:OMED

Receive News & Stock Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.